[go: up one dir, main page]

MX2023002200A - Composicion farmaceutica de forma de dosificacion individual para tratar o prevenir hipertension e hiperlipidemia. - Google Patents

Composicion farmaceutica de forma de dosificacion individual para tratar o prevenir hipertension e hiperlipidemia.

Info

Publication number
MX2023002200A
MX2023002200A MX2023002200A MX2023002200A MX2023002200A MX 2023002200 A MX2023002200 A MX 2023002200A MX 2023002200 A MX2023002200 A MX 2023002200A MX 2023002200 A MX2023002200 A MX 2023002200A MX 2023002200 A MX2023002200 A MX 2023002200A
Authority
MX
Mexico
Prior art keywords
hyperlipidemia
pharmaceutical composition
dosage form
single dosage
treating
Prior art date
Application number
MX2023002200A
Other languages
English (en)
Inventor
Ji Yeon Kim
Bo Hoon Kim
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MX2023002200A publication Critical patent/MX2023002200A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una forma de dosificación individual de composición farmacéutica para el tratamiento de hipertensión e hiperlipidemia. Según la presente invención, pueden garantizarse estabilidad y velocidades de disolución uniformes de fármacos mezclando composiciones que contienen fármacos deseados y formulando la mezcla para dar una forma de compartimento individual, mediante lo cual un procedimiento de fabricación se vuelve sencillo al tiempo que reduce los costes de procesamiento. Además, puede obtenerse una formulación que tiene equivalencia biológica a formulaciones individuales convencionales.
MX2023002200A 2020-08-25 2021-08-25 Composicion farmaceutica de forma de dosificacion individual para tratar o prevenir hipertension e hiperlipidemia. MX2023002200A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200107083A KR20220026641A (ko) 2020-08-25 2020-08-25 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물
PCT/KR2021/011353 WO2022045760A1 (ko) 2020-08-25 2021-08-25 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물

Publications (1)

Publication Number Publication Date
MX2023002200A true MX2023002200A (es) 2023-03-03

Family

ID=80353653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002200A MX2023002200A (es) 2020-08-25 2021-08-25 Composicion farmaceutica de forma de dosificacion individual para tratar o prevenir hipertension e hiperlipidemia.

Country Status (9)

Country Link
US (1) US20230321046A1 (es)
EP (1) EP4205730A4 (es)
KR (2) KR20220026641A (es)
CN (1) CN116018137A (es)
AU (1) AU2021331854B2 (es)
BR (1) BR112023003365A2 (es)
MX (1) MX2023002200A (es)
TW (1) TWI870615B (es)
WO (1) WO2022045760A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119868296A (zh) * 2025-02-14 2025-04-25 宁波大红鹰药业股份有限公司 一种奥美沙坦酯氨氯地平片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020002739A (ko) 2000-06-30 2002-01-10 박종섭 반도체 소자의 제조 방법
KR100795313B1 (ko) * 2006-09-05 2008-01-21 현대약품 주식회사 암로디핀 베실레이트를 포함하는 약학 조성물
EP2334668B1 (en) * 2008-09-05 2014-04-02 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing olmesartan medoxomil intermediate
CN101637609A (zh) * 2009-09-06 2010-02-03 王丽燕 含氨氯地平、aⅱ受体拮抗剂和他汀类药的药物组合物
TWI425026B (zh) 2011-09-19 2014-02-01 Everlight Chem Ind Corp 聚氨酯衍生物及其組成物及包括該衍生物的染料添加劑
IN2014MN01919A (es) * 2012-03-30 2015-07-10 Dae Woong Pharma
JP2015061828A (ja) * 2013-08-23 2015-04-02 第一三共株式会社 口腔内崩壊錠及びその製造方法
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
MX382254B (es) * 2015-06-30 2025-03-13 Hanmi Pharmaceutical Co Ltd Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.
ES2882672T3 (es) * 2015-07-08 2021-12-02 Hk Inno N Corp Composición farmacéutica que contiene amlodipino, valsartán, y rosuvastatina
EP3524578A4 (en) 2016-10-07 2020-10-07 Yulinghua Technology Co. Ltd SEWWATER TREATMENT PROCESS AND SYSTEM
CN107929287A (zh) * 2016-10-12 2018-04-20 武昌理工学院 一种包含氨氯地平的复方药物组合物及制备方法
KR20200009101A (ko) * 2017-10-17 2020-01-29 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
CN113811294B (zh) * 2019-02-26 2023-05-12 株式会社大熊制药 用于治疗或预防高血压和高脂血症的单一剂型药物组合物

Also Published As

Publication number Publication date
WO2022045760A1 (ko) 2022-03-03
TWI870615B (zh) 2025-01-21
BR112023003365A2 (pt) 2023-04-04
AU2021331854B2 (en) 2025-03-13
CN116018137A (zh) 2023-04-25
KR20250099675A (ko) 2025-07-02
EP4205730A4 (en) 2025-01-01
KR20220026641A (ko) 2022-03-07
US20230321046A1 (en) 2023-10-12
EP4205730A1 (en) 2023-07-05
TW202222310A (zh) 2022-06-16
AU2021331854A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
MX2025001020A (es) Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinal
MX2024002342A (es) Inhibidores del nlrp3.
CY1118211T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν ενωσεις λανθανιου
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
WO2002022132A8 (fr) Nouvelles compositions estro-progestatives topiques a effet systemique
EP4454703A3 (en) Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
YU81503A (sh) Postupak za proizvodnju farmaceutskog preparata sa niskom dozom, koji ima uniformnu raspodelu i snagu leka
WO2020118251A3 (en) Hypoxia targeting compositions and combinations thereof with a parp inhibitor and methods of use thereof
PH12021551232A1 (en) Haloallylamine compounds and application thereof
MX2021001145A (es) Formulación de liberación inmediata de una combinación triple de principios activos farmacéuticos, útil en el tratamiento del síndrome del ovario poliquístico.
MX2023005078A (es) Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.
WO2022247920A9 (zh) 喹啉胺类化合物、其制备方法及其在医药上的应用
MX2023002200A (es) Composicion farmaceutica de forma de dosificacion individual para tratar o prevenir hipertension e hiperlipidemia.
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
MX2021004551A (es) Composicion farmaceutica para el tratamiento de la anemia aplasica.
WO2020175922A3 (ko) 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물
ZA202400915B (en) Pharmaceutical composition and use thereof
JPWO2014013928A1 (ja) 安定化された内服用固形製剤
MX2023002403A (es) Composicion farmaceutica en forma de dosificacion individual para tratar o prevenir hipertension e hipercolesterolemia.
GB2618753A (en) Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance
AU2003214505A1 (en) Process for preparation of pharmaceutical composition containing antiretroviral protease inhibitor with improved bioavailability
SG161201A1 (en) Production process for nsaid-containing lozenges, their compositions, their medicinal use
EA029369B1 (ru) Фармацевтическая композиция в форме таблетки и способ ее получения
RU2010150760A (ru) Противоопухолевый агент, набор и способ лечения рака